<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2959914-A1" country="EP" doc-number="2959914" kind="A1" date="20151230" family-id="39690678" file-reference-id="313851" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="160452764" ucid="EP-2959914-A1"><document-id><country>EP</country><doc-number>2959914</doc-number><kind>A1</kind><date>20151230</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-15002036-A" is-representative="NO"><document-id mxw-id="PAPP193868496" load-source="docdb" format="epo"><country>EP</country><doc-number>15002036</doc-number><kind>A</kind><date>20080211</date><lang>EN</lang></document-id><document-id mxw-id="PAPP193868497" load-source="patent-office" format="original"><country>EP</country><doc-number>15002036.0</doc-number><date>20080211</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC162028085" ucid="EP-08725395-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>08725395</doc-number><kind>A</kind><date>20080211</date></document-id></priority-claim><priority-claim mxw-id="PPC162030356" ucid="EP-14001303-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>14001303</doc-number><kind>A</kind><date>20080211</date></document-id></priority-claim><priority-claim mxw-id="PPC162032519" ucid="US-90033807-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>90033807</doc-number><kind>P</kind><date>20070209</date></document-id></priority-claim><priority-claim mxw-id="PPC162034476" ucid="US-92466307-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>92466307</doc-number><kind>P</kind><date>20070524</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1988519571" load-source="docdb">A61K  31/00        20060101ALI20151027BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988520508" load-source="docdb">A61K  31/05        20060101ALI20151027BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988522016" load-source="docdb">A61P  25/00        20060101ALI20151027BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988522963" load-source="docdb">A61K  31/35        20060101ALI20151027BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988523207" load-source="docdb">A61K  31/335       20060101ALI20151027BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988523384" load-source="docdb">A61K  45/00        20060101ALI20151027BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988523540" load-source="docdb">A61P  25/28        20060101ALI20151027BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988525847" load-source="docdb">A61K  38/18        20060101AFI20151027BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988525995" load-source="docdb">A61K  31/395       20060101ALI20151027BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988526127" load-source="docdb">A61K  31/4015      20060101ALI20151027BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988526681" load-source="docdb">A61K  31/365       20060101ALI20151027BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1635352561" load-source="docdb" scheme="CPC">A61K  38/1825      20130101 FI20180526BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1635352562" load-source="docdb" scheme="CPC">A61K  31/4015      20130101 LI20180526BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1635352563" load-source="docdb" scheme="CPC">A61K  31/395       20130101 LI20180526BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1635352564" load-source="docdb" scheme="CPC">A61K  31/365       20130101 LI20180526BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1635352565" load-source="docdb" scheme="CPC">A61K  31/35        20130101 LI20180526BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1635352566" load-source="docdb" scheme="CPC">A61K  31/335       20130101 LI20180526BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1635352567" load-source="docdb" scheme="CPC">A61K  31/00        20130101 LI20180526BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1635352568" load-source="docdb" scheme="CPC">A61K  38/00        20130101 LA20180526BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1635352569" load-source="docdb" scheme="CPC">A61K  31/05        20130101 LI20180526BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT165549758" lang="DE" load-source="patent-office">THERAPEUTISCHE WIRKUNGEN VON BRYOLOGEN AUF DURCH KOPFTRAUMATA HERBEIGEFÜHRTE GEDÄCHTNISSTÖRUNGEN UND HIRNVERLETZUNGEN</invention-title><invention-title mxw-id="PT165549759" lang="EN" load-source="patent-office">THERAPEUTIC EFFECTS OF BRYOLOGS ON HEAD TRAUMA-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY</invention-title><invention-title mxw-id="PT165549760" lang="FR" load-source="patent-office">EFFETS THÉRAPEUTIQUES DES BRYOLOGUES SUR LES TROUBLES DE LA MÉMOIRE ET LES LÉSIONS CÉRÉBRALES SUITE À UN TRAUMATISME CRÂNIEN</invention-title><citations><patent-citations><patcit mxw-id="PCIT377586965" load-source="docdb" ucid="US-0213784-W" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>0213784</doc-number><kind>W</kind><date>20020502</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377585849" load-source="docdb" ucid="US-0307102-W" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>0307102</doc-number><kind>W</kind><date>20030307</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964369" load-source="docdb" ucid="US-4560774-A"><document-id format="epo"><country>US</country><doc-number>4560774</doc-number><kind>A</kind><date>19851224</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964370" load-source="docdb" ucid="US-4611066-A"><document-id format="epo"><country>US</country><doc-number>4611066</doc-number><kind>A</kind><date>19860909</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964371" load-source="docdb" ucid="US-4833257-A"><document-id format="epo"><country>US</country><doc-number>4833257</doc-number><kind>A</kind><date>19890523</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964372" load-source="docdb" ucid="US-5072004-A"><document-id format="epo"><country>US</country><doc-number>5072004</doc-number><kind>A</kind><date>19911210</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964373" load-source="docdb" ucid="US-5196447-A"><document-id format="epo"><country>US</country><doc-number>5196447</doc-number><kind>A</kind><date>19930323</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964374" load-source="docdb" ucid="US-5288514-A"><document-id format="epo"><country>US</country><doc-number>5288514</doc-number><kind>A</kind><date>19940222</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964376" load-source="docdb" ucid="US-5359115-A"><document-id format="epo"><country>US</country><doc-number>5359115</doc-number><kind>A</kind><date>19941025</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964375" load-source="docdb" ucid="US-5362899-A"><document-id format="epo"><country>US</country><doc-number>5362899</doc-number><kind>A</kind><date>19941108</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964377" load-source="docdb" ucid="US-5393897-A"><document-id format="epo"><country>US</country><doc-number>5393897</doc-number><kind>A</kind><date>19950228</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964378" load-source="docdb" ucid="US-5652232-A"><document-id format="epo"><country>US</country><doc-number>5652232</doc-number><kind>A</kind><date>19970729</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964380" load-source="docdb" ucid="US-5891870-A"><document-id format="epo"><country>US</country><doc-number>5891870</doc-number><kind>A</kind><date>19990406</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964379" load-source="docdb" ucid="US-5891906-A"><document-id format="epo"><country>US</country><doc-number>5891906</doc-number><kind>A</kind><date>19990406</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964383" load-source="docdb" ucid="US-5955501-A"><document-id format="epo"><country>US</country><doc-number>5955501</doc-number><kind>A</kind><date>19990921</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964382" load-source="docdb" ucid="US-5962498-A"><document-id format="epo"><country>US</country><doc-number>5962498</doc-number><kind>A</kind><date>19991005</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964381" load-source="docdb" ucid="US-5962504-A"><document-id format="epo"><country>US</country><doc-number>5962504</doc-number><kind>A</kind><date>19991005</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964384" load-source="docdb" ucid="US-6043270-A"><document-id format="epo"><country>US</country><doc-number>6043270</doc-number><kind>A</kind><date>20000328</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964385" load-source="docdb" ucid="US-6080784-A"><document-id format="epo"><country>US</country><doc-number>6080784</doc-number><kind>A</kind><date>20000627</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964386" load-source="docdb" ucid="US-6187568-B1"><document-id format="epo"><country>US</country><doc-number>6187568</doc-number><kind>B1</kind><date>20010213</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT377594808" load-source="docdb" ucid="US-9708141-W" dnum-type="application"><document-id format="epo"><country>US</country><doc-number>9708141</doc-number><kind>W</kind><date>19970509</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964387" load-source="docdb" ucid="WO-1991007087-A1"><document-id format="epo"><country>WO</country><doc-number>1991007087</doc-number><kind>A1</kind><date>19910530</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964388" load-source="docdb" ucid="WO-1992010092-A1"><document-id format="epo"><country>WO</country><doc-number>1992010092</doc-number><kind>A1</kind><date>19920625</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964389" load-source="docdb" ucid="WO-1993009668-A1"><document-id format="epo"><country>WO</country><doc-number>1993009668</doc-number><kind>A1</kind><date>19930527</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964390" load-source="docdb" ucid="WO-1993020242-A1"><document-id format="epo"><country>WO</country><doc-number>1993020242</doc-number><kind>A1</kind><date>19931014</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964391" load-source="docdb" ucid="WO-1994008051-A1"><document-id format="epo"><country>WO</country><doc-number>1994008051</doc-number><kind>A1</kind><date>19940414</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964392" load-source="docdb" ucid="WO-1997043268-A1"><document-id format="epo"><country>WO</country><doc-number>1997043268</doc-number><kind>A1</kind><date>19971120</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964393" load-source="docdb" ucid="WO-2004004641-A2"><document-id format="epo"><country>WO</country><doc-number>2004004641</doc-number><kind>A2</kind><date>20040115</date></document-id><sources><source name="SEA" category="X" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964394" load-source="docdb" ucid="WO-2004047857-A1"><document-id format="epo"><country>WO</country><doc-number>2004047857</doc-number><kind>A1</kind><date>20040610</date></document-id><sources><source name="SEA" category="A" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964395" load-source="docdb" ucid="WO-2006031337-A2"><document-id format="epo"><country>WO</country><doc-number>2006031337</doc-number><kind>A2</kind><date>20060323</date></document-id><sources><source name="SEA" category="X" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT384933441" load-source="docdb" ucid="WO-2008013573-A1"><document-id format="epo"><country>WO</country><doc-number>2008013573</doc-number><kind>A1</kind><date>20080131</date></document-id><sources><source name="SEA" category="AP" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>ASHENDEL ET AL., CANCER RES., vol. 43, 1983, pages 4333</text><sources><source mxw-id="PNPL57938843" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BAMES, J.M. ET AL., BR. J. PHARMACOL., vol. 98, 1989, pages 693</text><sources><source mxw-id="PNPL57938844" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BARNES, J.M. ET AL., PHARMACOL. BIOCHEM. BEHAV., vol. 35, 1990, pages 955 - 962</text><sources><source mxw-id="PNPL57938845" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BISHOP ET AL., J. BIOL. CHEM., vol. 261, 1986, pages 6993</text><sources><source mxw-id="PNPL57938846" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BLOHE ET AL., CANCER METAST. REV., vol. 13, 1994, pages 411</text><sources><source mxw-id="PNPL57938847" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BLONDELLE ET AL., TRENDS ANAL. CHEM., vol. 14, 1995, pages 83</text><sources><source mxw-id="PNPL57938848" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CHEN ET AL., JACCS, vol. 1 6, 1994, pages 266 1</text><sources><source mxw-id="PNPL57938849" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CHUNG ET AL., AM. J. PHYSIOL., vol. 265, 1993, pages C927</text><sources><source mxw-id="PNPL57938850" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>COLLINS ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 104, 1982, pages 1159</text><sources><source mxw-id="PNPL57938851" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>COS ALL, B. ET AL., PHARRNACOL. BIOCHEM. BEHAV., vol. 32, pages 777 - 785</text><sources><source mxw-id="PNPL57938852" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>COSTALL, B. ET AL., NEUROPHARMACOL., vol. 26, 1987, pages 195 - 200</text><sources><source mxw-id="PNPL57938853" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CRAWLEY, J. N., PHARMACOL. BIOCHEM. BEHAV., vol. 15, 1981, pages 695 - 699</text><sources><source mxw-id="PNPL57938854" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>DUG ET AL., BIOCHEM J., vol. 291, 1993, pages 329</text><sources><source mxw-id="PNPL57938855" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>FUJIKI ET AL., ADV. CANCER RES., vol. 49, 1987, pages 223</text><sources><source mxw-id="PNPL57938856" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>GENARO: "Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING CO.</text><sources><source mxw-id="PNPL57938857" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>GILBERT ET AL., BIOCHEMISTRY, vol. 34, 1995, pages 3916</text><sources><source mxw-id="PNPL57938858" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HENNINGS ET AL., CARCINOGENESIS, vol. 8, no. 9, 1987, pages 1343 - 1346</text><sources><source mxw-id="PNPL57938859" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HOLLISTER, L.E., PHARMACOPSYCHIAT, vol. 23, no. II, 1990, pages 33 - 36</text><sources><source mxw-id="PNPL57938860" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HOUSE ET AL., SCIENCE, vol. 238, 1987, pages 1726</text><sources><source mxw-id="PNPL57938861" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>IBARRETA ET AL., NEURO REPORT, vol. 10, no. 5&amp;6, 1999, pages 1035 - 40</text><sources><source mxw-id="PNPL57938862" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>ITO ET AL., BIOCHEMISTRY, vol. 25, 1986, pages 4179</text><sources><source mxw-id="PNPL57938863" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>J.F. KUO: "Protein Kinase C", 1994, OXFORD U. PRESS, pages: 171 - 198</text><sources><source mxw-id="PNPL57938864" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KAIBUCHI ET AL., J. BIOL. CHEM., vol. 258, 1983, pages 6701</text><sources><source mxw-id="PNPL57938865" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KANNO ET AL., J. LIPID RES., vol. 47, 2006, pages 1146</text><sources><source mxw-id="PNPL57938866" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KEN ET AL., JACCS, vol. 1 5, 1993, pages 252</text><sources><source mxw-id="PNPL57938867" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KIKKAWA ET AL., ANN. REV. BIOCHEM., vol. 58, 1989, pages 31</text><sources><source mxw-id="PNPL57938868" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KIKKAWA ET AL., J BIOL. CHENI, vol. 257, 1982, pages 13341</text><sources><source mxw-id="PNPL57938869" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MEINHARDT ET AL., ANTI-CANCER DRUGS, vol. 13, 2002, pages 725</text><sources><source mxw-id="PNPL57938870" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MORI ET AL., J. BIOCHEM, vol. 91, 1982, pages 427</text><sources><source mxw-id="PNPL57938871" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MUTTER ET AL., BIOORGANIC &amp; MEDICINAL CHEMISTRY, vol. 8, 2000, pages 1841 - 1860</text><sources><source mxw-id="PNPL57938872" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>NIEDEL ET AL., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 36</text><sources><source mxw-id="PNPL57938873" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>NISHIZUKA, CANCER, vol. 10, 1989, pages 1892</text><sources><source mxw-id="PNPL57938874" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>OGBOUME ET AL., ANTICANCER DRUGS, vol. 18, 2007, pages 357</text><sources><source mxw-id="PNPL57938875" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SZALLASI ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 3, 1994, pages 2118 - 24</text><sources><source mxw-id="PNPL57938876" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>VARTERASIAN ET AL., CLINICAL CANCER RESEARCH, vol. 6, 2000, pages 825 - 828</text><sources><source mxw-id="PNPL57938877" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>WENDER ET AL., AM CHEM SOC., vol. 124, 2002, pages 13648</text><sources><source mxw-id="PNPL57938878" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>WENDER ET AL., CURR DRUG DISCOV TECHNOL., vol. 1, 2004, pages 1</text><sources><source mxw-id="PNPL57938879" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>WENDER ET AL., ORG R LETT., vol. 8, 2006, pages 5299</text><sources><source mxw-id="PNPL57938880" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>WENDER ET AL., PROC NATL ACAD SCI U S A, vol. 95, 1998, pages 6624</text><sources><source mxw-id="PNPL57938881" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>WINKLER ET AL., J.ORG.CHEM., vol. 60, 1995, pages 1381</text><sources><source mxw-id="PNPL57938882" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>ZHANG ET AL., CANER RESEARCH, vol. 56, 1996, pages 802 - 808</text><sources><source mxw-id="PNPL57938883" load-source="docdb" name="APP"/></sources></nplcit></non-patent-citations></citations></technical-data><related-documents><relation type="division"><child-doc ucid="EP-15002036-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>15002036</doc-number><kind>A</kind><date>20080211</date></document-id><document-id load-source="patent-office" format="original"><country>EP</country><doc-number>15002036.0</doc-number><date>20080211</date></document-id></child-doc><parent-doc ucid="EP-08725395-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>08725395</doc-number><kind>A</kind><date>20080211</date></document-id><document-id load-source="patent-office" format="original"><country>EP</country><doc-number>08725395.1</doc-number><date>20080211</date></document-id><parent-grant-document ucid="EP-2121000-B1"><document-id><country>EP</country><doc-number>2121000</doc-number><kind>B1</kind><date>20150923</date></document-id></parent-grant-document></parent-doc></relation><relation type="division"><child-doc ucid="EP-15002036-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>15002036</doc-number><kind>A</kind><date>20080211</date></document-id><document-id load-source="patent-office" format="original"><country>EP</country><doc-number>15002036.0</doc-number><date>20080211</date></document-id></child-doc><parent-doc ucid="EP-14001303-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>14001303</doc-number><kind>A</kind><date>20140409</date></document-id><document-id load-source="patent-office" format="original"><country>EP</country><doc-number>14001303.8</doc-number><date>20140409</date></document-id></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR1103306985" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>BRNI NEUROSCIENCES INST</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103338109" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE</last-name></addressbook></applicant><applicant mxw-id="PPAR1101644009" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Blanchette Rockefeller Neurosciences, Institute</last-name><iid>101180957</iid><address><street>8 Medical Center Drive</street><city>Morgantown, WV 26505-3409</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR1103336284" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>ALKON DANIEL</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103323137" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>ALKON, DANIEL</last-name></addressbook></inventor><inventor mxw-id="PPAR1101644963" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>ALKON, DANIEL</last-name><address><street>4604 Dorset Ave</street><city>Chevy Chase, MD 20815-5448</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103328724" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>ZOHAR OFER</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103306982" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>ZOHAR, OFER</last-name></addressbook></inventor><inventor mxw-id="PPAR1101648859" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>ZOHAR, OFER</last-name><address><street>c/o Blanchette Rockefeller Neurosciences Institute Academic &amp; Research Building/Third Floor 9601 Medical Center Drive</street><city>Rockville, MD 20850</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR1101646749" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Kador &amp; Partner</last-name><iid>100060105</iid><address><street>Corneliusstrasse 15</street><city>80469 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS660713257" load-source="docdb">AT</country><country mxw-id="DS660730365" load-source="docdb">BE</country><country mxw-id="DS660628886" load-source="docdb">BG</country><country mxw-id="DS660789906" load-source="docdb">CH</country><country mxw-id="DS660707420" load-source="docdb">CY</country><country mxw-id="DS660713258" load-source="docdb">CZ</country><country mxw-id="DS660730366" load-source="docdb">DE</country><country mxw-id="DS660707421" load-source="docdb">DK</country><country mxw-id="DS660707422" load-source="docdb">EE</country><country mxw-id="DS660628411" load-source="docdb">ES</country><country mxw-id="DS660628903" load-source="docdb">FI</country><country mxw-id="DS660628904" load-source="docdb">FR</country><country mxw-id="DS660730379" load-source="docdb">GB</country><country mxw-id="DS660707427" load-source="docdb">GR</country><country mxw-id="DS660730380" load-source="docdb">HR</country><country mxw-id="DS660713267" load-source="docdb">HU</country><country mxw-id="DS660789907" load-source="docdb">IE</country><country mxw-id="DS660730381" load-source="docdb">IS</country><country mxw-id="DS660628905" load-source="docdb">IT</country><country mxw-id="DS660707428" load-source="docdb">LI</country><country mxw-id="DS660627876" load-source="docdb">LT</country><country mxw-id="DS660713268" load-source="docdb">LU</country><country mxw-id="DS660627877" load-source="docdb">LV</country><country mxw-id="DS660627878" load-source="docdb">MC</country><country mxw-id="DS660706332" load-source="docdb">MT</country><country mxw-id="DS660730382" load-source="docdb">NL</country><country mxw-id="DS660628906" load-source="docdb">NO</country><country mxw-id="DS660730387" load-source="docdb">PL</country><country mxw-id="DS660789908" load-source="docdb">PT</country><country mxw-id="DS660730388" load-source="docdb">RO</country><country mxw-id="DS660730389" load-source="docdb">SE</country><country mxw-id="DS660789909" load-source="docdb">SI</country><country mxw-id="DS660627883" load-source="docdb">SK</country><country mxw-id="DS660707429" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA166480862" lang="EN" load-source="patent-office"><p id="pa01" num="0001">The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brainderived neurotrophic factor (BDNF) or other neurotrophic factors to treat head trauma. Specifically, the present invention provides methods of treating head trauma comprising the steps of identifying a subject having suffered a head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma.</p></abstract><abstract mxw-id="PA166760674" lang="EN" source="EPO" load-source="docdb"><p>The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brainderived neurotrophic factor (BDNF) or other neurotrophic factors to treat head trauma. Specifically, the present invention provides methods of treating head trauma comprising the steps of identifying a subject having suffered a head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma.</p></abstract><description mxw-id="PDES98405563" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><p id="p0001" num="0001">This application claims benefit to <patcit id="pcit0001" dnum="US90033907P"><text>U. S. Provisional Application Serial No. 60/900,339, filed on February 9, 2007</text></patcit> and <patcit id="pcit0002" dnum="US924662P"><text>U. S. Provisional Application Serial No. 60/924,662</text></patcit>, filed on May 24, 2007, all of which are hereby incorporated herein by reference in their entireties.</p><heading id="h0001"><b>FIELD OF THE INVENTION</b></heading><p id="p0002" num="0002">The present invention relates to the treatment of head trauma with compounds that activate protein kinase C (PKC) or boost nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors.</p><heading id="h0002"><b>BACKGROUND OF THE INVENTION</b></heading><heading id="h0003"><b>A. <u>Head Trauma</u></b></heading><p id="p0003" num="0003">Head injury is a trauma to the head, that may or may not include injury to the brain (see also brain injury). The incidence (number of new cases) of head injury is 300 per 100,000 per year (0.3% of the population), with a mortality of 25 per 100,000 in North America and 9 per 100,000 in Britain. Head trauma is a common cause of childhood hospitalization.</p><p id="p0004" num="0004">Head injuries include both injuries to the brain and those to other parts of the head, such as the scalp and skull. Head injuries may be closed or open. A closed (non-missile) head injury is one in which the skull is not broken. A penetrating head injury occurs when an object pierces the skull and breaches the dura mater. Brain injuries may be diffuse, occurring over a wide area, or focal, located in a small, specific area. A head injury may cause a skull fracture, which may or may not be associated with injury to the brain. Some patients may have linear or depressed skull fractures. If intracranial hemorrhage, or bleeding within the brain occurs, a hematoma within the skull can put pressure on the brain. Types of intracranial hematoma include subdural, subarachnoid, extradural, and intraparenchymal hematoma.<!-- EPO <DP n="2"> --> Craniotomy surgeries are used in these cases to lessen the pressure by draining off blood. Head trauma is caused by a concussive event.</p><p id="p0005" num="0005">Brain injury can be at the site of impact, but can also be at the opposite side of the skull due to a contrecoup effect (the impact to the head can cause the brain to move within the skull, causing the brain to impact the interior of the skull opposite the head-impact). If the impact causes the head to move, the injury may be worsened, because the brain may ricochet inside the skull (causing additional impacts), or the brain may stay relatively still (due to inertia) but be hit by the moving skull.</p><heading id="h0004"><b>B. <u>Protein Kinase C</u></b></heading><p id="p0006" num="0006">PKC has been identified as one of the largest gene families of non-receptor serine-threonine protein kinases. Since the discovery of PKC in the early eighties by Nishizuka and coworkers (<nplcit id="ncit0001" npl-type="s"><text>Kikkawa et al. (1982) J. Biol. Chem. 257: 13341</text></nplcit>), and its identification as a major receptor for phorbol esters (<nplcit id="ncit0002" npl-type="s"><text>Ashendel et al. (1983) Cancer Res., 43: 4333</text></nplcit>), a multitude of physiological signaling mechanisms have been ascribed to this enzyme. The intense interest in PKC stems from its unique ability to be activated <i>in vitro</i> by calcium and diacylglycerol (and its phorbol ester mimetics), an effector whose formation is coupled to phospholipid turnover by the action of growth and differentiation factors.</p><p id="p0007" num="0007">The activation of PKC has been shown to improve learning and memory. (U.S. Patent Application Serial Nos. <patcit id="pcit0003" dnum="US0213784W"><text>PCT/US02/13784</text></patcit>; <patcit id="pcit0004" dnum="US0307102W"><text>PCT/US03/07102</text></patcit>; <patcit id="pcit0005" dnum="US60287721W"><text>60/287,721</text></patcit>; <patcit id="pcit0006" dnum="US60362081W"><text>60/362,081</text></patcit>; <patcit id="pcit0007" dnum="US10172005W"><text>10/172,005</text></patcit>; and <patcit id="pcit0008" dnum="US10476459W"><text>10/476,459</text></patcit>; each incorporated herein by reference in its entirety). Prior to the present disclosure, however, the PKC-mediated improvement of learning and memory has not been recognized as a mechanism for the treatment of post-head trauma memory deficits and brain injury. Also, the PKC activators disclosed herein, specifically those compounds that improve learning and memory, were not recognized as possessing brain function-restoring activity after head trauma.</p><p id="p0008" num="0008">Head trauma therapy has historically been limited to few treatment options available. Although many types of potential neuroprotectants have been tested in clinical trials, none has been approved for clinical use, because of ineffectiveness especially when used post-head trauma or associated toxicity. The compounds presented in this invention disclosure were<!-- EPO <DP n="3"> --> effective when the treatment was started one hour after the head trauma in the animal model at doses that have already been demonstrated to be well tolerated in humans (the bryostatin-1 doses). Compounds that target the protein kinase C (PKC) such as bryostatin-1, a direct PKC activator, and methylcatechol diacetic acid, a derivative of methylcatechol, an enhancer of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors, which is perhaps one of the PKC targets, have been found to have therapeutic value against brain injury and memory impairment induced with head trauma. The development of these substances as therapeutic in the treatment of head trauma is provided by this invention.</p><heading id="h0005"><b>SUMMARY OF THE INVENTION</b></heading><p id="p0009" num="0009">The present invention provides methods of treating head trauma comprising the steps of identifying a subject having suffered a head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma.</p><p id="p0010" num="0010">In one embodiment, the PKC activator is FGF-18, a macrocyclic lactone, a benzolactam, a pyrrolidinone, or a combination thereof. In a preferred embodiment, the macrocyclic lactone is a bryostatin or neristatin. In another embodiment, the neristatin is neristatin-1. In another embodiment, the bryostatin is bryostatin-1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18. More preferably, the bryostatin is bryostatin-1.</p><p id="p0011" num="0011">In another preferred embodiment, the pharmaceutical composition comprises 4-methylcatechol acetic acid (MCBA), other derivatives of methylcatechol, or a brain derived neurotrophic factor. MCBA and other derivatives of methylcatechol activate or upregulate nerve growth factor (NGF), brain derived neurotrophic factor (BDNF) or other neurotrophic factors. NGF activates, upregulates or enhances the activity of PKC which in turn upregulates, activates or enhances NGF.</p><p id="p0012" num="0012">In one embodiment, administration of the pharmaceutical compositions of the present invention is initiated within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days of said head trauma. In another embodiment, said administration is initiated between 1 and 2 days, 1 and 3<br/>
<!-- EPO <DP n="4"> -->days, 1 and 4 days, 1 and 5 or 1 and 7 days of said head trauma. In another embodiment, the administration of the pharmaceutical compositions of the present invention is initiated within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours of said head trauma. In yet another embodiment, the administration of the pharmaceutical compositions of the present invention is initiated between 1 and 3, 1 and 5, 1 and 10, 1 and 24, 3 and 5, 3 and 10, 3 and 24, 5 and 10, 5 and 24, or 10 and 24 hours after said head trauma. In yet another embodiment, the administration of the pharmaceutical compositions of the present invention is initiated after 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours after said head trauma. In yet another embodiment, the administration of the pharmaceutical compositions of the present invention is initiated after 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days after said head trauma.</p><p id="p0013" num="0013">In one embodiment, treatment comprising the administration of the pharmaceutical compositions of the present invention is continued for a duration of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 weeks.</p><heading id="h0006"><b>BRIEF DESCRIPTION OF THE FIGURE</b></heading><p id="p0014" num="0014"><ul><li><figref idrefs="f0001"><b>Figure 1</b></figref> depicts the escape latencies of mice after minimal traumatic brain injury (TBI)(30g) followed by 30ug/kg bryostatin injected intraperitoneally.</li><li><figref idrefs="f0002"><b>Figure 2</b></figref> depicts the escape latencies of mice after minimal traumatic brain injury (TBI) (30g):followed by 20ug/kg bryostatin injected intraperitoneally.</li><li><figref idrefs="f0003"><b>Figure 3</b></figref> depicts memory retention in mice after minimal TBI (30g) followed by 20ug/kg bryostatin injected intraperitoneally.</li></ul></p><heading id="h0007"><b>DETAILED DESCRIPTION OF THE INVENTION</b></heading><heading id="h0008"><b>A. Definitions</b></heading><p id="p0015" num="0015">As used herein, "administration" of a composition includes any route of administration, including oral subcutaneous, intraperitoneal, and intramuscular.</p><p id="p0016" num="0016">As used herein, "an effective amount" is an amount sufficient to reduce one or more symptoms associated with a head trauma.<!-- EPO <DP n="5"> --></p><p id="p0017" num="0017">As used herein, "protein kinase C activator" or "PKC activator" means a substance that increases the rate of the reaction catalyzed by protein kinase C by binding to the protein kinase C.</p><p id="p0018" num="0018">As used herein, the term "subject" means a mammal.</p><p id="p0019" num="0019">As used herein, the term "pharmaceutically acceptable carrier" means a chemical composition with which the active ingredient may be combined and which, following the combination, can be used to administer the active ingredient to a subject. As used herein, the term "physiologically acceptable" ester or salt means an ester or salt form of the active ingredient which is compatible with any other ingredients of the pharmaceutical composition, which is not deleterious to the subject to which the composition is to be administered.</p><p id="p0020" num="0020">As used herein, "pharmaceutically acceptable carrier" also includes, but is not limited to, one or more of the following: excipients; surface active agents; dispersing agents; inert diluents; granulating and disintegrating agents; binding agents; lubricating agents; sweetening agents; flavoring agents; coloring agents; preservatives; physiologically degradable compositions such as gelatin; aqueous vehicles and solvents; oily vehicles and solvents; suspending agents; dispersing or wetting agents; emulsifying agents, demulcents; buffers; salts; thickening agents; fillers; emulsifying agents; antioxidants; antibiotics; antifungal agents; stabilizing agents; and pharmaceutically acceptable polymeric or hydrophobic materials. Other "additional ingredients" which may be included in the pharmaceutical compositions of the invention are known in the art and described, for example in <nplcit id="ncit0003" npl-type="b"><text>Genaro, ed., 1985, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa</text></nplcit>., which is incorporated herein by reference.</p><p id="p0021" num="0021">The formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single- or multi-dose unit.<!-- EPO <DP n="6"> --></p><p id="p0022" num="0022">Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions of the invention is contemplated include, but are not limited to, humans and other primates, and other mammals.</p><p id="p0023" num="0023">Despite progress toward the development of new therapeutic agents and availability of several animal models, there is still a pressing need for improved animal models for screening</p><heading id="h0009">B. Animal Models of Learning and Memory</heading><p id="p0024" num="0024">The area of memory and learning impairment is rich in animal models that are able to demonstrate different features of memory and learning processes. (<i>See, for example,</i> <nplcit id="ncit0004" npl-type="s"><text>Hollister, L.E., 1990, Pharmacopsychiat., 23, (Suppl II) 33-36</text></nplcit>). The available animal models of memory loss and impaired learning involve measuring the ability of animals to remember a discrete event. These tests include the Morris Water Maze and the passive avoidance procedure. In the Morris Water Maze, animals are allowed to swim in a tank divided into four quadrants, only one of which has a safety platform beneath the water. The platform is removed and the animals are tested for how long they search the correct quadrant verse the incorrect quadrants. In the passive avoidance procedure the animal remembers the distinctive environment in which a mild electric shock is delivered and avoids it on a second occasion. A variant of the passive avoidance procedure makes use of a rodent's preference for dark enclosed environments over light open ones. Further discussion can be found in<nplcit id="ncit0005" npl-type="s"><text> Crawley, J. N., 1981, Pharmacol. Biochem. Behav., 15, 695-699</text></nplcit>; <nplcit id="ncit0006" npl-type="s"><text>Costall, B. et al, 1987, Neuropharmacol., 26, 195-200</text></nplcit>; <nplcit id="ncit0007" npl-type="s"><text>Costall, B. et al., 1989, Pharmacol. Biochem. Behav., 32, 777-785</text></nplcit>; <nplcit id="ncit0008" npl-type="s"><text>Barnes, J.M. et al., 1989, Br. J. Pharmacol., 98 (Suppl) 693P</text></nplcit>; <nplcit id="ncit0009" npl-type="s"><text>Barnes, J.M. et al., 1990, Pharmacol. Biochem. Behav., 35, 955-962</text></nplcit>.<!-- EPO <DP n="7"> --></p><heading id="h0010"><b>C. Protein Kinase C (PKC)</b></heading><p id="p0025" num="0025">The PKC gene family consists presently of 11 genes which are divided into four subgroups: 1) classical PKCα, β<sub>1</sub>, β<sub>2</sub> (β<sub>1</sub> and β<sub>2</sub> are alternatively spliced forms of the same gene) and γ, 2) novel PKCδ, ε, η, and θ, 3) atypical PKCζ, λ, η and <i>i</i> and 4) PKC µ. PKC µ resembles the novel PKC isoforms but differs by having a putative transmembrane domain (reviewed by <nplcit id="ncit0010" npl-type="s"><text>Blohe et al. (1994) Cancer Metast. Rev. 13: 411</text></nplcit>; <nplcit id="ncit0011" npl-type="s"><text>Ilug et al. (1993) Biochem J. 291: 329</text></nplcit>;<nplcit id="ncit0012" npl-type="s"><text> Kikkawa et al. (1989) Ann. Rev. Biochem. 58: 31</text></nplcit>). The α, β<sub>1</sub>, β<sub>2</sub> and γ isoforms are C<sup>2+</sup>, phospholipid and diacylglycerol-dependent and represent the classical isoforms of PKC, whereas the other isoforms are activated by phospholipid and diacylglycerol but are not dependent on Ca<sup>2+</sup>. All isoforms encompass 5 variable (V1-V5) regions, and the α, β and γ isoforms contain four (C1-C4) structural domains which are highly conserved. All isoforms except PKC α, β and γ lack the C2 domain, the λ η and isoforms also lack nine of two cysteine-rich zinc finger domains in C1 to which diacylglycerol binds. The C1 domain also contains the pseudosubstrate sequence which is highly conserved among all isoforms, and which serves an autoregulartory function by blocking the substrate-binding site to produce an inactive conformation of the enzyme (<nplcit id="ncit0013" npl-type="s"><text>House et al. (1987) Science 238, 1726</text></nplcit>).</p><p id="p0026" num="0026">Because of these structural features, diverse PKC isoforms are thought to have highly specialized roles in signal transduction in response to physiological stimuli (<nplcit id="ncit0014" npl-type="s"><text>Nishizuka (1989) Cancer 10: 1892</text></nplcit>), as well as in neoplastic transformation and differentiation (<nplcit id="ncit0015" npl-type="b"><text>Glazer (1994) Protein Kinase C, J.F. Kuo, ed., Oxford U. Press at pages 171-198</text></nplcit>). For a discussion of known PKC modulators see <patcit id="pcit0009" dnum="US9708141W"><text>PCT/US97/08141</text></patcit>, <patcit id="pcit0010" dnum="US5652232A"><text>U.S. Patent Nos. 5,652,232</text></patcit>; <patcit id="pcit0011" dnum="US6080784A"><text>6,080,784</text></patcit>; <patcit id="pcit0012" dnum="US5891906A"><text>5,891,906</text></patcit>; <patcit id="pcit0013" dnum="US5962498A"><text>5,962,498</text></patcit>; <patcit id="pcit0014" dnum="US5955501A"><text>5,955,501</text></patcit>; <patcit id="pcit0015" dnum="US5891870A"><text>5,891,870</text></patcit> and <patcit id="pcit0016" dnum="US5962504A"><text>5,962,504</text></patcit> (each incorporated herein by reference in its entirety).</p><p id="p0027" num="0027">There is increasing evidence that the individual PKC isozymes play different, sometimes opposing, roles in biological processes, providing two directions for pharmacological exploitation. One is the design of specific (preferably, isozyme specific) inhibitors of PKC. This approach is complicated by the act that the catalytic domain is not the domain primarily responsible for the isotype specificity of PKC. The other approach is to develop isozyme-selective, regulatory site-directed PKC activators. These may provide a way to override the<!-- EPO <DP n="8"> --> effect of other signal transduction pathways with opposite biological effects. Alternatively, by inducing down-regulation of PKC after acute activation, PKC activators may cause long term antagonism. Bryostatin is currently in clinical trials as an anti-cancer agent. The bryostatins are known to bind to the regulatory domain of PKC and to activate the enzyme. Bryostatins are examples of isozyme-selective activators of PKC. (see for example <patcit id="pcit0017" dnum="WO9743268A"><text>WO 97/43268</text></patcit>; incorporated herein by reference in its entirety). For a discussion of known PKC modulators see <patcit id="pcit0018" dnum="US9708141W"><text>PCT/US97/08141</text></patcit>, <patcit id="pcit0019" dnum="US5652232A"><text>U.S. Patent Nos. 5,652,232</text></patcit>; <patcit id="pcit0020" dnum="US6043270A"><text>6,043,270</text></patcit>; <patcit id="pcit0021" dnum="US6080784A"><text>6,080,784</text></patcit>; <patcit id="pcit0022" dnum="US5891906A"><text>5,891,906</text></patcit>; <patcit id="pcit0023" dnum="US5962498A"><text>5,962,498</text></patcit>; <patcit id="pcit0024" dnum="US5955501A"><text>5,955,501</text></patcit>; <patcit id="pcit0025" dnum="US5891870A"><text>5,891,870</text></patcit> and <patcit id="pcit0026" dnum="US5962504A"><text>5,962,504</text></patcit> (each of which is incorporated herein by reference in its entirety).</p><p id="p0028" num="0028">Several classes of PKC activators have been identified. Phorbol esters, however, are not suitable compounds for eventual drug development because of their tumor promotion activity, (<nplcit id="ncit0016" npl-type="s"><text>Ibarreta et al. (1999) Neuro Report 10(5&amp;6): 1035-40</text></nplcit>). Of particular interest are macrocyclic lactones (i.e. bryostatin class and neristatin class) that act to stimulate PKC. Of the bryostatin class compounds., bryostatin-1 has been shown to activate PKC and proven to be devoid of tumor promotion activity. Bryostatin-1, as a PKC activator, is also particularly useful since the dose response curve of bryostatin-1 is biphasic. Additionally, bryostatin-1 demonstrates differential regulation of PKC isozymes, including PKCα, PKCδ and PKCε. Bryostatin-1 has undergone toxicity and safety studies in animals and humans and is actively investigated as an anti-cancer agent. Bryostatin-1's use in the studies has determined that the main adverse reaction in humans is myalgia. One example of an effective dose is 20 or 30 µg/kg per dose by intraperitoneal injection.</p><p id="p0029" num="0029">Several classes of PKC activators have been identified. Phorbol esters, however, are not suitable compounds for eventual drug development because of their tumor promotion activity, (<nplcit id="ncit0017" npl-type="s"><text>Ibarreta et al. (1999) Neuro Report 10(5&amp;6): 1035-40</text></nplcit>). Of particular interest are macrocyclic lactones (i.e. bryostatin class and neristatin class) that act to stimulate PKC. Of the bryostatin class compounds, bryostatin-1 has been shown to activate PKC and proven to be devoid of tumor promotion activity. Bryostatin-1, as a PKC activator, is also particularly useful since the dose response curve of bryostatin-1 is biphasic. Additionally, bryostatin-1 demonstrates differential regulation of PKC isozymes, including PKCα, PKCδ and PKCε. Bryostatin-1 has undergone toxicity and safety studies in animals and humans and is actively<!-- EPO <DP n="9"> --> investigated as an anti-cancer agent. Bryostatin-1's use in the studies has determined that the main adverse reaction in humans is myalgia. One example of an effective dose is 20 or 30 µg/kg per dose by intraperitoneal injection.</p><p id="p0030" num="0030">Macrocyclic lactones, and particularly bryostatin-1, are described in <patcit id="pcit0027" dnum="US4560774A"><text>U.S. Patent 4,560,774</text></patcit> (incorporated herein by reference in its entirety). Macrocyclic lactones and their derivatives are described elsewhere in <patcit id="pcit0028" dnum="US6187568B"><text>U.S. Patent 6,187,568</text></patcit>, <patcit id="pcit0029" dnum="US6043270A"><text>U.S. Patent 6,043,270</text></patcit>, <patcit id="pcit0030" dnum="US5393897A"><text>U.S. Patent 5,393,897</text></patcit>, <patcit id="pcit0031" dnum="US5072004A"><text>U.S. Patent 5,072,004</text></patcit>, <patcit id="pcit0032" dnum="US5196447A"><text>U.S. Patent 5,196,447</text></patcit>, <patcit id="pcit0033" dnum="US4833257A"><text>U.S. Patent 4,833,257</text></patcit>, and <patcit id="pcit0034" dnum="US4611066A"><text>U.S. Patent 4,611,066</text></patcit> (each incorporated herein by reference in its entirety). The above patents describe various compounds and various uses for macrocyclic lactones including their use as an antiinflammatory or anti-tumor agent. (<nplcit id="ncit0018" npl-type="s"><text>Szallasi et al. (1994) Journal of Biological Chemistry 269(3): 2118-24</text></nplcit>; <nplcit id="ncit0019" npl-type="s"><text>Zhang et al. (1996) Caner Research 56: 802-808</text></nplcit>;<nplcit id="ncit0020" npl-type="s"><text> Hennings et al. (1987) Carcinogenesis 8(9): 1343-1346</text></nplcit>; <nplcit id="ncit0021" npl-type="s"><text>Varterasian et al. (2000) Clinical Cancer Research 6: 825-828</text></nplcit>; <nplcit id="ncit0022" npl-type="s"><text>Mutter et al. (2000) Bioorganic &amp; Medicinal Chemistry 8: 1841-1860</text></nplcit>)(each incorporated herein by reference in its entirety).</p><p id="p0031" num="0031">As will also be appreciated by one of ordinary skill in the art, macrocyclic lactone compounds and their derivatives, particularly the bryostatin class, are amenable to combinatorial synthetic techniques and thus libraries of the compounds can be generated to optimize pharmacological parameters, including, but not limited to efficacy and safety of the compositions. Additionally, these libraries can be assayed to determine those members that preferably modulate α-secretase and/or PKC.</p><p id="p0032" num="0032">Combinatorial libraries high throughput screening of natural products and fermentation broths has resulted in the discovery of several new drugs. At present, generation and screening of chemical diversity is being utilized extensively as a major technique for the discovery of lead compounds, and this is certainly a major fundamental advance in the area of drug discovery. Additionally, even after a "lead" compound has been identified, combinatorial techniques provide for a valuable tool for the optimization of desired biological activity. As will be appreciated, the subject reaction readily lend themselves to the creation of combinatorial libraries of compounds for the screening of pharmaceutical, or other biological or medically-related activity or material-related qualities. A combinatorial library for the purposes of the<br/>
<!-- EPO <DP n="10"> -->present invention is a mixture of chemically related compounds, which may be screened together for a desired property; said libraries may be in solution or covalently linked to a solid support. The preparation of many related compounds in a single reaction greatly reduces and simplifies the number of screening processes that need to be carried out. Screening for the appropriate biological property may be done by conventional methods. Thus, the present invention also provides methods for determining the ability of one or more inventive compounds to bind to effectively modulate α-secretase and/or PKC.</p><p id="p0033" num="0033">A variety of techniques are available in the art for generating combinatorial libraries described below, but it will be understood that the present invention is not intended to be limited by the foregoing examples and descriptions. (<i>See, for example,</i> <nplcit id="ncit0023" npl-type="s"><text>Blondelle et al. (1995) Trends Anal. Chem. 14: 83</text></nplcit>; <patcit id="pcit0035" dnum="US5359115A"><text>U.S. Patents 5,359,115</text></patcit>; <patcit id="pcit0036" dnum="US5362899A"><text>5,362,899</text></patcit>; <patcit id="pcit0037" dnum="US5288514A"><text>U.S. 5,288,514</text></patcit>: <patcit id="pcit0038" dnum="WO9408051A"><text>PCT publication WO 94/08051</text></patcit>; <nplcit id="ncit0024" npl-type="s"><text>Chen et al. (1994) JACCS 1 6:266 1</text></nplcit>: <nplcit id="ncit0025" npl-type="s"><text>Kerr et al. (1993) JACCS I 1 5:252</text></nplcit>; <patcit id="pcit0039" dnum="WO9210092A"><text>PCT publications WO92/10092</text></patcit>, <patcit id="pcit0040" dnum="WO9309668A"><text>WO93/09668</text></patcit>; <patcit id="pcit0041" dnum="WO9107087A"><text>WO91/07087</text></patcit>; and <patcit id="pcit0042" dnum="WO9320242A"><text>WO93/20242</text></patcit>; each of which is incorporated herein by reference). Accordingly, a variety of libraries on the order of about 16 to 1,000,000 or more diversomers can be synthesized and screened for a particular activity or property.</p><p id="p0034" num="0034">Analogs of bryostatin, commonly referred to as bryologs, are one particular class of PKC activators that are suitable for use in the methods of the present invention. The following Table summarizes structural characteristics of several bryologs, demonstrating that bryologs vary greatly in their affinity for PKC (from 0.25 nM to 10 µM). Structurally, they are all similar. While bryostatin-1 has two pyran rings and one 6-membered cyclic acetal, in most bryologs one of the pyrans of bryostatin-1 is replaced with a second 6-membered acetal ring. This modification reduces the stability of bryologs, relative to bryostatin-1, for example, in both strong acid or base, but has little significance at physiological pH. Bryologs also have a lower molecular weight (ranging from about 600 to 755), as compared to bryostatin-1 (988), a property which facilitates transport across the blood-brain barrier.
<tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="22mm"/><colspec colnum="2" colname="col2" colwidth="25mm"/><colspec colnum="3" colname="col3" colwidth="11mm"/><colspec colnum="4" colname="col4" colwidth="74mm"/><thead><row><entry align="center" valign="top">Name</entry><entry align="center" valign="top">PKC Affin (nM)</entry><entry align="center" valign="top">MW</entry><entry align="center" valign="top">Description</entry></row></thead><tbody><row><entry>Bryostatin 1</entry><entry align="right">1.35</entry><entry align="center">988</entry><entry>2 pyran + 1 cyclic acetal + macrocycle</entry></row><row><entry>Analog 1</entry><entry align="right">0.25</entry><entry align="center">737</entry><entry>1 pyran + 2 cyclic acetal + macrocycle</entry></row><row><entry>Analog 2</entry><entry align="right">6.50</entry><entry align="center">723</entry><entry>1 pyran + 2 cyclic acetal + macrocycle</entry></row><row><entry>Analog 7a</entry><entry align="right">-</entry><entry align="center">642</entry><entry>1 pyran + 2 cyclic acetals + macrocycle</entry></row><!-- EPO <DP n="11"> --><row><entry>Analog 7b</entry><entry align="right">297</entry><entry align="center">711</entry><entry>1 pyran + 2 cyclic acetals + macrocycle</entry></row><row><entry>Analog 7c</entry><entry align="right">3.4</entry><entry align="center">726</entry><entry>1 pyran +2 cyclic acetals + macrocycle</entry></row><row><entry>Analog 7d</entry><entry align="right">10000</entry><entry align="center">745</entry><entry>1 pyran + 2 cyclic acetals + macrocycle, acetylated</entry></row><row><entry>Analog 8</entry><entry align="right">8.3</entry><entry align="center">754</entry><entry>2 cyclic acetals + macrocycle</entry></row><row><entry>Analog 9</entry><entry align="right">10000</entry><entry align="center">599</entry><entry>2 cyclic acetals</entry></row></tbody></tgroup></table></tables></p><p id="p0035" num="0035">Analog 1 (<nplcit id="ncit0026" npl-type="s"><text>Wender et al. (2004) Curr Drug Discov Technol. 1: 1</text></nplcit>; <nplcit id="ncit0027" npl-type="s"><text>Wender et al. (1998) Proc Natl Acad Sci U S A 95: 6624</text></nplcit>;<nplcit id="ncit0028" npl-type="s"><text> Wender et al. (2002) Am Chem Soc. 124: 13648</text></nplcit> (each incorporated herein by reference in their entireties)) possesses the highest affinity for PKC. This bryolog is about100 times more potent than bryostatin-1. Only Analog 1 exhibits a higher affinity for PKC than bryostatin. Analog 2, which lacks the A ring of bryostatin-1 is the simplest analog that maintains high affinity for PKC. In addition to the active bryologs, Analog 7d, which is acetylated at position 26, has virtually no affinity for PKC.
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="99" he="49" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="105" he="46" img-content="chem" img-format="tif"/></chemistry></p><p id="p0036" num="0036">B-ring bryologs are also suitable for use in the methods of the present invention. These synthetic bryologs have affinities in the low nanomolar range (<nplcit id="ncit0029" npl-type="s"><text>Wender et al. (2006) Org<!-- EPO <DP n="12"> --> Lett. 8: 5299</text></nplcit> (incorporated herein by reference in its entirety)). The B-ring bryologs have the advantage of being completely synthetic, and do not require purification from a natural source.
<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="111" he="42" img-content="chem" img-format="tif"/></chemistry>
<chemistry id="chem0004" num="0004"><img id="ib0004" file="imgb0004.tif" wi="113" he="42" img-content="chem" img-format="tif"/></chemistry>
PKC binding affinities for B-ring bryologs</p><p id="p0037" num="0037">A third class of suitable bryostatin analogs is the A-ring bryologs. These bryologs have slightly lower affinity for PKC than bryostatin I (6.5, 2.3, and 1.9 nM for bryologs 3, 4, and 5, respectively) but have a lower molecular weight.</p><p id="p0038" num="0038">A number of derivatives of diacylglycerol (DAG) bind to and activate protein kinase C (<nplcit id="ncit0030" npl-type="s"><text>Niedel et al. (1983) Proc. Natl. Acad. Sci. USA 80: 36</text></nplcit>;<nplcit id="ncit0031" npl-type="s"><text> Mori et al. (1982) J. Biochem (Tokyo) 91: 427</text></nplcit>; <nplcit id="ncit0032" npl-type="s"><text>Kaibuchi et al. (1983) J. Biol. Chem. 258: 6701</text></nplcit>). However, DAG and DAG derivatives are of limited value as drugs. Activation of PKC by diacylglycerols is transient, because they are rapidly metabolized by diacylglycerol kinase and lipase (<nplcit id="ncit0033" npl-type="s"><text>Bishop et al. (1986) J. Biol. Chem. 261: 6993</text></nplcit>; <nplcit id="ncit0034" npl-type="s"><text>Chung et al. (1993) Am. J. Physiol. 265: C927</text></nplcit>; incorporated herein by reference in their entireties). The fatty acid substitution determines the strength of activation. Diacylglycerols having an unsaturated fatty acid are most active. The stereoisomeric<br/>
<!-- EPO <DP n="13"> -->configuration is also critical. Fatty acids with a 1,2-sn configuration are active, while 2,3-sn-diacylglycerols and 1,3-diacylglycerols do not bind to PKC. Cis-unsaturated fatty acids are synergistic with diacylglycerols. In one embodiment of the present invention, the term "PKC activator" expressly excludes DAG or DAG derivatives, such as phorbol esters.</p><p id="p0039" num="0039">Isoprenoids are PKC activators suitable for use in the methods of the present invention. Farnesyl thiotriazole, for example, is a synthetic isoprenoid that activates PKC with a Kd of 2.5 µM. Farnesyl thiotriazole, for example, is equipotent with dioleoylglycerol (<nplcit id="ncit0035" npl-type="s"><text>Gilbert et al. (1995) Biochemistry 34: 3916</text></nplcit>; incorporated herein by reference in its entirety), but does not possess hydrolyzable esters of fatty acids. Farnesyl thiotriazole and related compounds represent a stable, persistent PKC activator. Because of its low MW (305.5) and absence of charged groups, farnesyl thiotriazole would readily cross the blood-brain barrier.
<chemistry id="chem0005" num="0005"><img id="ib0005" file="imgb0005.tif" wi="89" he="15" img-content="chem" img-format="tif"/></chemistry></p><p id="p0040" num="0040">Octylindolactam V is a non-phorbol protein kinase C activator related to teleocidin. The advantages of octylindolactam V, specifically the (-)-enantiomer, include greater metabolic stability, high potency (<nplcit id="ncit0036" npl-type="s"><text>Fujiki et al. (1987) Adv. Cancer Res. 49: 223</text></nplcit>; <nplcit id="ncit0037" npl-type="s"><text>Collins et al. (1982) Biochem. Biophys. Res. Commun. 104: 1159</text></nplcit>; each incorporated herein by reference in its entirety)(EC<sub>50</sub> = 29nM) and low molecular weight that facilitates transport across the blood brain barrier.
<chemistry id="chem0006" num="0006"><img id="ib0006" file="imgb0006.tif" wi="70" he="48" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="14"> --></p><p id="p0041" num="0041">Gnidimacrin is a daphnane-type diterpene that displays potent antitumor activity at concentrations of 0.1 - 1 nM against murine leukemias and solid tumors. It acts as a PKC activator at a concentration of ≈3 nM in K562 cells, and regulates cell cycle progression at the G1/S phase through the suppression of Cdc25A and subsequent inhibition of cyclin dependent kinase 2 (Cdk2) (100% inhibition achieved at 5 ng/ml). Gnidimacrin is a heterocyclic natural product similar to bryostatin, but somewhat smaller (MW = 774.9).
<chemistry id="chem0007" num="0007"><img id="ib0007" file="imgb0007.tif" wi="63" he="51" img-content="chem" img-format="tif"/></chemistry></p><p id="p0042" num="0042">Iripallidal is a bicyclic triterpenoid isolated from Iris pallida. Iripallidal displays anti-proliferative activity in a NCI 60 cell line screen with GI50 (concentration required to inhibit growth by 50%) values from micromolar to nanomolar range. It binds to PKCα with high affinity (Ki = 75.6 nM). It induces phosphorylation of ERK1/2 in a RasGRP3-dependent manner. M.W. 486.7. Iripallidal is only about half the size of bryostatin and lacks charged groups.
<chemistry id="chem0008" num="0008"><img id="ib0008" file="imgb0008.tif" wi="77" he="30" img-content="chem" img-format="tif"/></chemistry></p><p id="p0043" num="0043">Ingenol [43] is a diterpenoid related to phorbol but possesses much less toxicity. It is derived from the milkweed plant Euphorbia peplus. Ingenol 3,20-dibenzoate, for example, competes with [3H]phorbol dibutyrate for binding to PKC (Ki for binding=240 nM) (<nplcit id="ncit0038" npl-type="s"><text>Winkler et al. (1995) J.Org.Chem. 60: 1381</text></nplcit>; incorporated herein by reference). Ingenol-3-angelate<!-- EPO <DP n="15"> --> possesses antitumor activity against squamous cell carcinoma and melanoma when used topically (<nplcit id="ncit0039" npl-type="s"><text>Ogboume et al. (2007) Anticancer Drugs. 18: 357</text></nplcit>; incorporated herein by reference).
<chemistry id="chem0009" num="0009"><img id="ib0009" file="imgb0009.tif" wi="72" he="39" img-content="chem" img-format="tif"/></chemistry></p><p id="p0044" num="0044">Napthalenesulfonamides, including N-(n-heptyl)-5-chloro-1-naphthalenesulfonamide (SC-10) and N-(6-Phenylhexyl)-5-chloro-1-naphthalenesulfonamide, are members of another class of PKC activators. SC-10 activates PKC in a calcium-dependent manner, using a mechanism similar to that of phosphatidylserine (<nplcit id="ncit0040" npl-type="s"><text>Ito et al. (1986) Biochemistry 25: 4179</text></nplcit>; incorporated herein by reference). Naphthalenesulfonamides act by a different mechanism from bryostatin and would be expected to show a synergistic effect with bryostatin or a member of another class of PKC activators. Structurally, naphthalenesulfonamides are similar to the calmodulin (CaM) antagonist W-7, but are reported to have no effect on CaM kinase.<!-- EPO <DP n="16"> -->
<chemistry id="chem0010" num="0010"><img id="ib0010" file="imgb0010.tif" wi="68" he="33" img-content="chem" img-format="tif"/></chemistry></p><p id="p0045" num="0045">The linoleic acid derivative DCP-LA (2-[(2-pentylcyclopropyl)methyl] cyclopropaneoctanoic acid) is one of the few known isoform-specific activators of PKC known. DCP-LA selectively activates PKCε with a maximal effect at 100 nM. (<nplcit id="ncit0041" npl-type="s"><text>Kanno et al. (2006) J. Lipid Res. 47: 1146</text></nplcit>). Like SC-10, DCP-LA interacts with the phosphatidylserine binding site of PKC, instead of the diacylglycerol binding site.</p><p id="p0046" num="0046">An alternative approach to activating PKC directly is to increase the levels of the endogenous activator, diacylglycerol. Diacylglycerol kinase inhibitors such as 6-(2-(4-[(4-fluorophenyl)phenylmethylene]-1-piperidinyl)ethyl)-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one (R59022) and [3-[2-[4-(bis-(4-fluorophenyl)methylene]piperidin-1-yl)ethyl]-2,3-dihydro-2-thioxo-4(1H)-quinazolinone (R59949) enhance the levels of the endogenous ligand diacylglycerol, thereby producing activation of PKC (<nplcit id="ncit0042" npl-type="s"><text>Meinhardt et al. (2002) Anti-Cancer Drugs 13: 725</text></nplcit>).</p><p id="p0047" num="0047">Growth factor activators, such as the 4-methyl catechol derivatives, such as 4-methylcatechol acetic acid (MCBA), that stimulate the synthesis and/or activation of growth factors such as NGF and BDNF, also activate PKC as well as convergent pathways responsible for synaptogenesis and/or neuritic branching.</p><p id="p0048" num="0048">All books, articles, patents or other publications and references are hereby incorporated by reference in their entireties. Reference to any compound herein includes the racemate as well as the single enantiomers</p><heading id="h0011"><b>EXAMPLES</b></heading><p id="p0049" num="0049">The following Examples serve to further illustrate the present invention and are not to be construed as limiting its scope in any way.<!-- EPO <DP n="17"> --></p><heading id="h0012"><b><u>EXAMPLE 1: ANIMAL MODEL OF HEAD TRAUMA</u></b></heading><p id="p0050" num="0050">Minimal traumatic brain injury (TBI) was produced in mice by a concussive event using a 30g mass. One hour post trauma, the mice received 20 or 30 µg bryostatin per kg doses by intraperitoneal injection. The injections were repeated twice weekly for a total of 5 treatments. The effects on learning and memory of bryostatin treatment in treated animals was tested in the Morris Water Maze.</p><heading id="h0013"><b><u>EXAMPLE 2: MORRIS WATER MAZE</u></b></heading><p id="p0051" num="0051">In the Morris Water Maze, animals were allowed to swim in a tank divided into four quadrants, only one of which had a safety platform beneath the water. The platform was removed and the animals were tested for how long they searched the correct quadrant versus the incorrect quadrants. In the passive avoidance procedure the animal remembers the distinctive environment in which a mild electric shock is delivered and avoids it on a second occasion.</p><heading id="h0014"><b><u>EXAMPLE 3: BRYOSTATIN (30 UG/KG) AND TREATMENT OF MINIMAL TBI</u></b></heading><p id="p0052" num="0052">Minimal traumatic brain injury (TBI) was produced in mice by a concussive event using a 30g mass. One hour post trauma, the mice received 30 µg bryostatin per kg doses by intraperitoneal injection. The injections were repeated twice weekly for a total of 5 treatments. The escape latencies in a Morris Water Maze of mice treated with bryostatin after minimal TBI were compared to animals with minimal TBI, control animals receiving no TBI onbryostatin, and animals receiving bryostatin only. The results are shown in <figref idrefs="f0001"><b>Figure 1</b></figref><b>.</b></p><heading id="h0015"><u><b>EXAMPLE 4: BRYOSTATIN (20 UG/KG) AND TREATMENT OF MINIMAL</b> TBI</u></heading><p id="p0053" num="0053">Minimal traumatic brain injury (TBI) was produced in mice by a concussive event using a 30g mass. One hour post trauma, the mice received 20 µg bryostatin per kg doses by intraperitoneal injection. The injections were repeated twice weekly for a total of 5 treatments. The escape latencies in a Morris Water Maze of mice treated with bryostatin after minimal TBI were compared to animals with minimal TBI, control animals receiving no TBI or bryostatin, and animals receiving bryostatin only. The results are shown in <figref idrefs="f0002"><b>Figure 2</b></figref><b>.</b> The memory retention of each treatment or control group is tabulated in <figref idrefs="f0003"><b>Figure 3</b></figref><b>.</b><!-- EPO <DP n="18"> --></p><p id="p0054" num="0054">In the following clauses, preferred embodiments of the invention are described:
<ol><li>1. A method of treating head trauma comprising the steps of identifying a subject having suffered a head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA), or other derivatives of methylcatechol, and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma.</li><li>2. The method of clause 1, wherein the PKC activator is FGF-18, a macrocyclic lactone, a benzolactam, a pyrrolidinone, or a combination thereof.</li><li>3. The method of clause 2, wherein the macrocyclic lactone is a bryostatin or neristatin.</li><li>4. The method of clause 3, wherein the bryostatin is bryostatin- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18.</li><li>5. The method of clause 4, wherein the bryostatin is bryostatin-1.</li><li>6. The method of clause 3, wherein the neristatin is neristatin- 1.</li><li>7. The method of clause 1, wherein the pharmaceutical composition comprises 4- methylcatechol acetic acid.</li><li>8. The method of clause 1, wherein said administration is initiated within 1 day of said head trauma.</li><li>9. The method of clause 1, wherein said administration is initiated within 2 days of said head trauma.</li><li>10. The method of clause 1, wherein said administration is initiated within 3 days of said head trauma.</li><li>11. The method of clause 1, wherein said administration is initiated between 1 and 2 days of said head trauma.</li><li>12. The method of clause 1, wherein said administration is initiated between 1 and 3 days of said head trauma.</li><li>13. The method of clause 1, wherein the treatment is continued for a duration of 1 week.<!-- EPO <DP n="19"> --></li><li>14. The method of clause 1, wherein the treatment is continued for a duration of 2 weeks.</li><li>15. The method of clause 1, wherein the treatment is continued for a duration of 3 weeks.</li><li>16. The method of clause 1, wherein the treatment is continued for a duration of 4 weeks.</li><li>17. The method of clause 1, wherein the treatment is continued for a duration of 6 week.</li><li>18. The method of clause 1, wherein said treatment reverses head trauma-induced brain injury.</li><li>19. The method of clause 1, wherein said treatment reverses head trauma-induced memory impairment.</li></ol></p></description><claims mxw-id="PCLM90460528" lang="EN" load-source="patent-office"><!-- EPO <DP n="20"> --><claim id="c-en-0001" num="0001"><claim-text>A pharmaceutical composition comprising a protein kinase C (PKC) activator and a pharmaceutically acceptable carrier for use in a medicament effective to treat at least one symptom of head trauma, wherein the PKC activator is selected from the group consisting of bryologs and a combination thereof.</claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>The pharmaceutical composition of claim 1, wherein the administration of said pharmaceutical composition is initiated at a time period chosen from within 1 day, within 2 days, within 3 days, between 1 and 2 days, between 1 and 3 days, between 1 and 4 days, between 1 and 5 and between 1 and 7 days of said head trauma.</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>The pharmaceutical composition of claim 1, wherein the treatment is continued for a duration chosen from 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks and 12 weeks.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>The pharmaceutical composition of claim 1, wherein said treatment reverses head trauma-induced brain injury or memory impairment.</claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>The pharmaceutical composition of claim 1, wherein the bryolog is a B-ring bryolog or A-ring bryolog.</claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>The pharmaceutical composition of claim 5, wherein the B-ring or A-ring bryolog has a molecular weight from about 600 to 755 and an affinity for PKC from about 0.25 nM to 10 µM.</claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>The pharmaceutical composition of claim 1, wherein the bryolog is<!-- EPO <DP n="21"> -->
<chemistry id="chem0011" num="0011"><img id="ib0011" file="imgb0011.tif" wi="105" he="45" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-en-0008" num="0008"><claim-text>The pharmaceutical composition of claim 6, wherein the B-ring byrolog is selected from the group consisting of
<chemistry id="chem0012" num="0012"><img id="ib0012" file="imgb0012.tif" wi="129" he="98" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-en-0009" num="0009"><claim-text>The pharmaceutical composition of claim 5, wherein the A-ring bryolog is
<chemistry id="chem0013" num="0013"><img id="ib0013" file="imgb0013.tif" wi="46" he="45" img-content="chem" img-format="tif"/></chemistry>
and R is t-Bu, Ph, or (CH<sub>2</sub>)<sub>3</sub>p-Br-Ph.</claim-text></claim></claims><drawings mxw-id="PDW20423158" load-source="patent-office"><!-- EPO <DP n="22"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="134" he="178" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="23"> --><figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="135" he="173" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="24"> --><figure id="f0003" num="3"><img id="if0003" file="imgf0003.tif" wi="120" he="198" img-content="drawing" img-format="tif"/></figure></drawings><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="157" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="157" he="233" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
